Medicinova vs Prokidney
Prokidney is the larger business, with $893,000 of revenue in fiscal 2025 against $409,657 for Medicinova (2.2 times as much). Prokidney grew faster (1075.0% against -59.0%). Medicinova kept more of each dollar of sales as profit: a net margin of -2928.8% against -7725.2%.
| Latest fiscal year | MedicinovaMNOV, 2025 | ProkidneyPROK, 2025 |
|---|---|---|
| Revenue | $409,657 | $893,000 |
| Revenue growth | -59.0% | 1075.0% |
| Net income | −$12.0m | −$69.0m |
| Operating margin | -3242.5% | -18477.8% |
| Net margin | -2928.8% | -7725.2% |
| Return on equity | -23.1% | — |
| Free cash flow | −$9.8m | −$135m |
| Cash | $30.8m | $109m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $0 |
| Employees | — | 231 |
| Market value | $70.9m | $227m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 1 sales | 0 buys, 10 sales |